Julio Licinio

Last updated

Julio Licinio
Julio Licinio.jpg
Born1958
Belo Horizonte, Minas Gerais, Brazil
NationalityAmerican, Australian, Brazilian
EducationMD, Federal University of Bahia, 1982.

PhD, Psychiatry, Flinders University, 2017.

MBA, Samuel Curtis Johnson Graduate School of Management, Cornell University, 2019.

MS, Healthcare Leadership,

Contents

Weill Cornell Graduate School of Medical Sciences, Cornell University, 2019.
Alma mater Federal University of Bahia
Known for Pharmacogenomics, biology of depression
Spouse Ma-Li Wong
Scientific career
Fields Psychiatry
Institutions Yale University, NIH Intramural Research Program, UCLA, University of Miami Miller School of Medicine, John Curtin School of Medical Research, South Australian Health and Medical Research Institute and Flinders University, State University of New York Upstate Medical University
Thesis The biology of leptin: Effects on endocrine regulation and its replacement treatment (2017)

Julio Licinio is an Australian American psychiatrist who is SUNY Distinguished Professor [1] at State University of New York Upstate Medical University in Syracuse, New York. He is simultaneously Matthew Flinders Distinguished Professor of Psychiatry at Flinders University in Adelaide. [2] [3] Licinio has been Senior Vice President for Academic and Health Affairs, as well as Executive Dean, College of Medicine. [4] Licinio is the founding and current chief editor of three journals from Springer Nature, Molecular Psychiatry , [5] Translational Psychiatry , [6] and Discover Mental Health. [7]

His area of scientific expertise is precision medicine with a focus on pharmacogenomics, [8] as well as the biology of depression, and he has edited books on both topics. [9] [10] He has also published research on translational psychiatry, as well as on obesity and the possible link between obesity, depression, and antidepressants. [11] [12] [13]

Education

Licinio originally received his MD from the Federal University of Bahia in 1982 and completed an internship in internal medicine at the University of São Paulo from 1983 to 1984. He then moved to the United States and completed training in endocrinology at The University of Chicago, and psychiatry at Albert Einstein in the Bronx as well as at Weill Cornell Medical College.[ citation needed ] In 2009, Licinio moved to Australia, where he completed a PhD in psychiatry at Flinders University in 2017.[ citation needed ] Licinio is registered as a specialist in psychiatry by the Australian Health Practitioner Regulation Agency. [14] He is board certified in psychiatry by the American Board of Psychiatry and Neurology and he is a Fellow of the Royal Australian and New Zealand College of Psychiatrists, the Australian Academy of Health and Medical Sciences (elected 2015), [15] the American Psychiatric Association, and the American College of Neuropsychopharmacology.[ citation needed ] In May 2019 Licinio completed an MBA from the Samuel Curtis Johnson Graduate School of Management, Cornell University and an MS in Healthcare Leadership from Weill Cornell Graduate School of Medical Sciences. [16]

Career

Licinio was an assistant professor of psychiatry at Yale University, then he was a Unit Chief within the Clinical Neurodocrinology Branch of the National Institute of Mental Health at the NIH Intramural Research Program (1993–1999), and later was professor of psychiatry and medicine/endocrinology at the David Geffen School of Medicine at UCLA from 1999 until 2006, where he had multiple roles, such as Founding Director of three NIH funded programs: the Interdepartmental Center on Clinical Pharmacology. [2] In 2006, he was appointed the Miller Professor of Psychiatry, Chairman of Psychiatry & Behavioral Sciences and subsequently Associate Dean for project development, responsible for starting the Clinical and Translational Science Institute at the University of Miami Miller School of Medicine, where he worked until 2009, [17] when he moved to Australia as Director of the John Curtin School of Medical Research. Licinio returned to the US in 2017 as Senior Vice President for Academic and Health Affairs, Executive Dean, College of Medicine, and in 2019 he was appointed SUNY Distinguished Professor in the Departments of Psychiatry, Pharmacology, Medicine and Neuroscience & Physiology at State University of New York Upstate Medical University in Syracuse, New York. [18]

During 1993–2001, Licinio was a temporary advisor to the World Health Organization (WHO), co-chairing ten WHO scientific meetings in seven countries, and co-edited the resulting ten books containing the proceedings of those meetings, mostly focused on the role of dysthymia in neurological disorders. [19] [20]

In 2005–2010, Licinio was a member of the United States Secretary of Health and Human Services Advisory Committee of Genetics Health and Society (SACGHS). [21] The key issue addressed during his term was the Genetic Information Nondiscrimination Act (GINA), which was strongly supported by the SACGHS. GINA was enacted on 21 May 2008 (Pub.L. 110–233, 122 Stat. 881) [22] as an Act of Congress in the United States, designed to prohibit the use of genetic information in health insurance and employment. [23]

Licinio was the head of the Australian node of the German-Australian Institute for Translational Medicine (GAITM), directed by Stefan R. Bornstein. [24] He has published collaboratively with 190 colleagues from 54 institutions, located in 19 countries, including Nobel Laureates Andrew Schally [25] and Rita Levi-Montalcini. [26]

Honors and awards

Teaching

Licinio directed three graduate training programs with master's degrees in translational investigation, for physician-scientists, at UCLA (supported by an NIH K30 award), [29] University of Miami (supported by an NIH K30 award), and Australian National University. He also created and obtained NIH T32, [30] NIH K12, [31] and PhRMA Foundation (2004 Center of Excellence in Clinical Pharmacology) funding for the UCLA Interdepartmental Clinical Pharmacology Training Program, of which he was founding director (1999–2006). [32] Licinio was the recipient of an NIH K24 award [33] to mentor early career physician-scientists (2002–2007). [34]

Scientific research

According to Google Scholar, Licinio has an h-index of 86, with 38,965 citations. [35] He has published 309 papers indexed in PubMed, [36] as well as 13 books.

Licinio is known for his research into leptin and its role in conveying a feeling of satiety. For example, in 2002, he identified three people from Turkey who suffered from a genetic disorder called leptin deficiency – the only three adults known at that time to have this disorder – all of whom were severely overweight as a result. [37] He then administered daily leptin injections to each of them, and found that after ten months, the patients had lost half of his or her original body weight. [38] [39] He discovered that despite being produced by a dispersed mass of fat cells, leptin is secreted in a highly organised manner with distinct pulsatility and circadian rhythm and that it appears to regulate the minute-to-minute rhythms of several endocrine axes, such as the hypothalamic-pituitary-adrenal axis, the hypothalamic–pituitary–thyroid axis, and the hypothalamic–pituitary–gonadal axis. [40] [41] [42] Licinio and his colleagues were the first to suggest that leptin may have antidepressant effects, [43] a concept that was subsequently extended by other groups. [44] [45] He also contributed to pioneer the concept that leptin has pro-cognitive effects in humans. [46]

With his group, Licinio conducted work on the precision medicine and pharmacogenomics of depression that started in 2000 as part of the National Institute of General Medical Sciences NIH Pharmacogenomics Research Network (PGRN). [47] In that project, he and his team studied a Mexican-American population with major depressive disorder in the city of Los Angeles, in the context of an extensive process of community engagement, [48] which received Certificates of Commendation both from the California State Legislature and the United States Congress. He contributed the Mexican American samples to the International HapMap Project. [49] His pharmacogenetics research has resulted in several publications on predictors of antidepressant treatment response in this population. [50] [51] [52] [53] [54]

Wong and Licinio contributed some of the earliest work on the role of cytokines and immune mediators in the brain, with implications for the underlying biology of major depressive disorder, [55] and published scientific articles on the localisation of gene expression for interleukin 1 receptor antagonist, [56] interleukin 1 receptor, type I (IL1R1), also known as CD121a (Cluster of Differentiation 121a), [57] and inducible nitric oxide synthase (iNOS) [58] in mammalian brain. They also showed that interleukin 1 receptor antagonist is an endogenous neuroprotective agent. [59] They have shown that the central and peripheral cytokine compartments are integrated but differentially regulated. [60] In collaboration with colleagues at Columbia University Licinio and his team showed that inflammation-mediated up-regulation of secretory sphingomyelin phosphodiesterase in vivo represents a possible link between inflammatory cytokines and atherogenesis. [61] Licinio's line of research examining the effects of peripheral inflammation in brain, behaviour and metabolism is ongoing in their lab. [62]

In a more recent and ongoing line of research, Licinio and collaborators are examining the effects of the human microbiota and the microbiome–gut–brain (MGB) axis in obesity with diabetes and on behaviors relevant to depression and schizophrenia, an emerging area which opens potentially novel avenues for the treatment of psychiatric disorders. [63] [64] [65] [66] [67] [68] [69]

Licinio and Wong have recently[ when? ] published a paper on the effects of climate change on mental health, [70] which Springer Nature highlighted as the leading article for their Sustainable Development Goal (SDG) 13: Climate Action. [71]

Public engagement

Licinio wrote four book reviews for Science, including a commentary on the current diagnostic system in psychiatry, the American Psychiatry Association (APA)'s "Diagnostic and Statistical Manual of Mental Disorders", Fifth Edition (DSM-5) and the controversial exhibit on Sigmund Freud at the US Library of Congress. [72] [73] [74] [75] Licinio writes a blog on science-related matters for the general public. [76] In 2018-2019 Licinio was a member of the New York State Governor's Suicide Prevention Task Force, representing the State University of New York. [77]

Personal life

Licinio's wife, Ma-Li Wong, is also an expert on depression, pharmacogenomics and psychoneuroimmunology; they have worked together for over 25 years, and have co-authored over 200 papers, [78] [79] and co-edited two multi-authored books on pharmacogenomics [80] and the biology of depression. [81]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Major depressive disorder</span> Mental disorder involving persistent low mood, low self-esteem, and loss of interest

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since.

<span class="mw-page-title-main">Ketamine</span> Dissociative anesthetic and anti-depressant

Ketamine is a dissociative anesthetic used medically for induction and maintenance of anesthesia. It is also used as a treatment for depression and pain management. It is a novel compound that was derived from phencyclidine in 1962 in pursuit of a safer anesthetic with fewer hallucinogenic effects.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Citalopram</span> SSRI antidepressant

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is typically taken orally. In some European countries, it is sometimes given intravenously to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

<span class="mw-page-title-main">Mirtazapine</span> Antidepressant medication

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression. Its effects may take up to four weeks, but can also manifest as early as one to two weeks. It is often used in cases of depression complicated by anxiety or insomnia. The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants. It is taken by mouth.

<span class="mw-page-title-main">Amitriptyline</span> Tricyclic antidepressant

Amitriptyline, sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat major depressive disorder, a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line therapy for these indications.

<span class="mw-page-title-main">Imipramine</span> Antidepressant

Imipramine, sold under the brand name Tofranil, among others, is a tricyclic antidepressant (TCA) mainly used in the treatment of depression. It is also effective in treating anxiety and panic disorder. Imipramine is taken by mouth.

Dysthymia, also known as persistent depressive disorder (PDD), is a mental and behavioral disorder, specifically a disorder primarily of mood, consisting of similar cognitive and physical problems as major depressive disorder, but with longer-lasting symptoms. The concept was used by Robert Spitzer as a replacement for the term "depressive personality" in the late 1970s.

<span class="mw-page-title-main">Desipramine</span> Antidepressant

Desipramine, sold under the brand name Norpramin among others, is a tricyclic antidepressant (TCA) used in the treatment of depression. It acts as a relatively selective norepinephrine reuptake inhibitor, though it does also have other activities such as weak serotonin reuptake inhibitory, α1-blocking, antihistamine, and anticholinergic effects. The drug is not considered a first-line treatment for depression since the introduction of selective serotonin reuptake inhibitor (SSRI) antidepressants, which have fewer side effects and are safer in overdose.

<span class="mw-page-title-main">Clomipramine</span> Antidepressant

Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). It is used in the treatment of various conditions, most-notably obsessive–compulsive disorder but also many other disorders, including panic disorder, major depressive disorder, trichotilomania, body dysmorphic disorder and chronic pain. It has also been notably used to treat premature ejaculation and the cataplexy associated with narcolepsy.

Treatment-resistant depression is a term used in psychiatry to describe people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. Definitions of treatment-resistant depression vary, and they do not include a resistance to psychological therapies. Inadequate response has most commonly been defined as less than 50% reduction in depressive symptoms following treatment with at least one antidepressant medication, although definitions vary widely. Some other factors that may contribute to inadequate treatment are: a history of repeated or severe adverse childhood experiences, early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, cognitive impairment, low income and other socio-economic variables, and concurrent medical conditions, including comorbid psychiatric disorders. Cases of treatment-resistant depression may also be referred to by which medications people with treatment-resistant depression are resistant to. In treatment-resistant depression adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019.

<span class="mw-page-title-main">Fluoxetine</span> SSRI antidepressant

Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

The relationship between antidepressant use and suicide risk is a subject of medical research and has faced varying levels of debate. This problem was thought to be serious enough to warrant intervention by the U.S. Food and Drug Administration to label greater likelihood of suicide as a risk of using antidepressants. Some studies have shown that the use of certain antidepressants correlate with an increased risk of suicide in some patients relative to other antidepressants. However, these conclusions have faced considerable scrutiny and disagreement: A multinational European study indicated that antidepressants decrease risk of suicide at the population level, and other reviews of antidepressant use claim that there is not enough data to indicate antidepressant use increases risk of suicide.

<span class="mw-page-title-main">Gustavo Turecki</span>

Gustavo Turecki is a Canadian psychiatrist, suicidologist, neuroscientist who is a professor at McGill University in Montreal, Quebec, Canada. He holds a Tier 1 Canada Research Chair Tier in Major Depressive Disorder and Suicide. He is the sitting Chair of the Department of Psychiatry at McGill University, the Scientific Director of the Douglas Research Centre, and the Psychiatrist-in-Chief of the Centre intégré universitaire de santé et de services sociaux de l’Ouest-de-l’Île-de-Montréal. He works at the Douglas Mental Health University Institute, where he heads both the McGill Group for Suicide Studies and the Depressive Disorders Program, and is the co-director of the Douglas Bell-Canada Brain Bank.

<span class="mw-page-title-main">Arketamine</span> Chemical compound

Arketamine (developmental code names PCN-101, HR-071603), also known as (R)-ketamine or (R)-(−)-ketamine, is the (R)-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the S(+) enantiomer of ketamine, arketamine is biologically active; however, it is less potent as an NMDA receptor antagonist and anesthetic and thus has never been approved or marketed for clinical use as an enantiopure drug. Arketamine is currently in clinical development as a novel antidepressant.

<span class="mw-page-title-main">Hydroxynorketamine</span> Chemical compound

Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine. It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine. As of late 2019, (2R,6R)-HNK is in clinical trials for the treatment of depression.

Andrew M. McIntosh is a UK academic psychiatrist. He is Professor of Biological Psychiatry at the Centre for Clinical Brain Sciences, University of Edinburgh, and is an affiliate member of the Centre for Genomic and Experimental Medicine at the University of Edinburgh. The main focus of his research is using genomic and neuroimaging approaches to better understand the causes and causal consequences of Major Depressive Disorder.

References

  1. ↑ "SUNY honors two with Distinguished Faculty rank". SUNY Upstate Medical University. Archived from the original on 8 May 2019. Retrieved 8 May 2019.
  2. 1 2 "Professor Julio Licinio". Flinders University. Archived from the original on 25 November 2015. Retrieved 25 November 2015.
  3. ↑ "Congratulations Professor Julio Licinio". John Curtin School of Medical Research . 21 March 2013. Archived from the original on 22 November 2014. Retrieved 15 October 2014.
  4. ↑ "Julio Licinio, MD, PhD, named senior vice president and dean of the College of Medicine". SUNY Upstate Medical University. Archived from the original on 8 May 2019. Retrieved 8 May 2019.
  5. ↑ "Molecular Psychiatry". Springer Nature . 19 October 2021. Retrieved 19 October 2021.
  6. ↑ "Translational Psychiatry". Springer Nature . 19 October 2021. Retrieved 19 October 2021.
  7. ↑ "Discover Mental Health". Springer Nature . 19 November 2021. Retrieved 19 October 2021.
  8. ↑ "Professor Julio Licinio: The pharmacogenomics of depression at ANU". Australia National University . 19 September 2010. Archived from the original on 17 April 2016. Retrieved 15 October 2014.
  9. ↑ Licinio, Julio; Wong, Ma-Li, eds. (12 October 2014). Pharmacogenomics: The Search for Individualized Therapies. Wiley Online Library. doi:10.1002/3527600752. ISBN   978-3527303809. S2CID   215530144.
  10. ↑ Licinio, Julio; Wong, Ma-Li, eds. (12 October 2014). Biology of Depression: From Novel Insights to Therapeutic Strategies. Wiley Online Library. doi:10.1002/9783527619672. ISBN   9783527619672.
  11. ↑ Garrett, Catherine (31 May 2010). "Stateline lunches with Professor Julio Licinio, the new head of the John Curtin School of Medical Research". Australia: ABC News. Archived from the original on 19 November 2014. Retrieved 15 October 2014.
  12. ↑ Metherell, Mark (14 May 2011). "A bitter pill: from depression to obesity". The Sydney Morning Herald . Archived from the original on 9 February 2014. Retrieved 28 January 2014.
  13. ↑ Mastronardi, C.; Paz-Filho, G. J.; Valdez, E.; Maestre-Mesa, J.; Licinio, J.; Wong, M. L. (March 2011). "Long-term body weight outcomes of antidepressant-environment interactions". Molecular Psychiatry. 16 (3): 265–272. doi:10.1038/mp.2010.122. PMC   3042256 . PMID   21135853.
  14. ↑ "Australian Health Practitioner Regulation Agency". 13 October 2014. Archived from the original on 10 October 2014. Retrieved 13 October 2014.
  15. ↑ "Fellowship of the Australian Academy of Health & Medical Sciences – October 2015" (PDF). Australian Academy of Health & Medical Sciences. Archived (PDF) from the original on 28 November 2016. Retrieved 12 October 2018.
  16. ↑ "Julio Licinio, MD". Doximity . Retrieved 13 December 2022.
  17. ↑ "Julio Licinio". The Conversation . 28 April 2011. Retrieved 29 October 2013.
  18. ↑ "Julio Licinio, MD/PhD". State University of New York Upstate Medical University . Retrieved 21 January 2023.
  19. ↑ J. Licinio; L. Prilipko; C. L. Bolis, eds. (1997). Dysthymia in neurological disorders: proceedings of WHO meeting. World Health Organization. hdl:10665/65927.
  20. ↑ Health, World Health Organization Division of Mental; Gold, P.; Bolis, C. L.; Licinio, J. (1997). J. Licinio; L. C. L. Bolis; P. Gold (eds.). Dysthymia : from clinical neuroscience to treatment. World Health Organization. hdl:10665/65928.
  21. ↑ "Secretary's Advisory Committee on Genetics, Health, and Society". NIH . 13 October 2014. Archived from the original on 17 October 2014. Retrieved 13 October 2014.
  22. ↑ "Genetic Information Non-discrimination Act of 2008". United States Government Printing Office . 13 October 2014. Archived from the original on 27 October 2014. Retrieved 13 October 2014.
  23. ↑ "H.R. 493 – Genetic Information Nondiscrimination Act of 2007" (PDF). Office of Management and Budget . 25 April 2007. Archived (PDF) from the original on 24 September 2015. Retrieved 12 October 2014.
  24. ↑ "German-Australian Institute for Translational Medicine (GAITM)". Dresden University of Technology . 13 October 2014. Archived from the original on 5 October 2014. Retrieved 13 October 2014.
  25. ↑ Schmid, J.; Ludwig, B.; Schally, A. V.; Steffen, A.; Ziegler, C. G.; Block, N. L.; Koutmani, Y.; Brendel, M. D.; Karalis, K. P.; Simeonovic, C. J.; Licinio, J.; Ehrhart-Bornstein, M.; Bornstein, S. R. (16 August 2011). "Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase". Proceedings of the National Academy of Sciences of the United States of America. 108 (33): 13722–13727. Bibcode:2011PNAS..10813722S. doi: 10.1073/pnas.1110965108 . PMC   3158163 . PMID   21825133.
  26. ↑ Bornstein, S. R.; Ehrhart-Bornstein, M.; Androutsellis-Theotokis, A.; Eisenhofer, G.; Vukicevic, V.; Licinio, J.; Wong, M.-L.; Calissano, P.; Nisticò, G.; Preziosi, P.; Levi-Montalcini, R. (April 2012). "Chromaffin cells: the peripheral brain". Molecular Psychiatry. 17 (4): 354–358. doi: 10.1038/mp.2011.176 . PMID   22249377.
  27. ↑ "Professor Julio Licinio: Academic Status and Matthew Flinders Distinguished Professor, College of Medicine and Public Health". Flinders University . Retrieved 26 July 2020.
  28. ↑ "SUNY Board of Trustees Appoints 18 Faculty to Distinguished Ranks". State University of New York Board . Retrieved 26 July 2020.
  29. ↑ "K30 Clinical Research Curriculum Award (CRCA)". NIH . 13 October 2014. Archived from the original on 17 October 2014. Retrieved 13 October 2014.
  30. ↑ "Institutional National Research Service Award". NIH . 13 October 2014. Archived from the original on 17 October 2014. Retrieved 13 October 2014.
  31. ↑ "Physician Scientist Award". NIH . 13 October 2014. Archived from the original on 12 October 2014. Retrieved 13 October 2014.
  32. ↑ "UCLA Interdepartmental Clinical Pharmacology Training Program". UCLA . 13 October 2014. Archived from the original on 19 October 2014. Retrieved 13 October 2014.
  33. ↑ "Midcareer Investigator Award in Patient-Oriented Research". NIH . 13 October 2014. Archived from the original on 17 October 2014. Retrieved 13 October 2014.
  34. ↑ "Clinical Neuroendocrinology of Leptin". NIH . Retrieved 21 January 2023.
  35. ↑ "Julio Licinio". Google Scholar . Archived from the original on 1 November 2013. Retrieved 8 May 2019.
  36. ↑ "PubMed-indexed articles by J Licinio". PubMed . 13 October 2014. Archived from the original on 17 October 2014. Retrieved 13 October 2014.
  37. ↑ "The Role of Leptin in Weight Loss". ABC News. 7 August 2002. Archived from the original on 4 March 2016. Retrieved 25 March 2014.
  38. ↑ Licinio, J.; Caglayan, S.; Ozata, M.; Yildiz, B. O.; de Miranda, P. B.; O'Kirwan, F.; Whitby, R.; Liang, L.; Cohen, P.; Bhasin, S.; Krauss, R. M.; Veldhuis, J. D.; Wagner, A. J.; DePaoli, A. M.; McCann, S. M.; Wong, M.-L. (9 March 2004). "Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults". Proceedings of the National Academy of Sciences of the United States of America. 101 (13): 4531–4536. Bibcode:2004PNAS..101.4531L. doi: 10.1073/pnas.0308767101 . PMC   384781 . PMID   15070752.
  39. ↑ Woznicki, Katrina (24 July 2002). "Leptin helps Turkish family lose weight". UPI . Archived from the original on 26 March 2014. Retrieved 25 March 2014.
  40. ↑ Licinio, J.; Mantzoros, C.; Negrão, A. B.; Cizza, G.; Wong, M.-L.; Bongiorno, P. B.; Chrousos, G. P.; Karp, B.; Allen, C.; Flier, J. S.; Gold, P. W. (May 1997). "Human leptin levels are pulsatile and inversely related to pituitary-adrenal function". Nature Medicine. 3 (5): 575–579. doi:10.1038/nm0597-575. PMID   9142131. S2CID   6065035.
  41. ↑ Licinio, J.; Negrão, A. B.; Mantzoros, C.; Kaklamani, V.; Wong, M.-L.; Bongiorno, P. B.; Mulla, A.; Cearnal, L.; Veldhuis, J. D.; Flier, J. S.; McCann, S. M.; Gold, P. W. (3 March 1998). "Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women". Proceedings of the National Academy of Sciences of the United States of America. 95 (5): 2541–2546. Bibcode:1998PNAS...95.2541L. doi: 10.1073/pnas.95.5.2541 . PMC   19406 . PMID   9482922.
  42. ↑ Mantzoros, C. S.; Ozata, M.; Negrao, A. B.; Suchard, M. A.; Ziotopoulou, M.; Caglayan, S.; Elashoff, R. M.; Cogswell, R. J.; Negro, P.; Liberty, V.; Wong, M.-L.; Veldhuis, J.; Ozdemir, I. C.; Gold, P. W.; Flier, J. S.; Licinio, J. (July 2001). "Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans". Journal of Clinical Endocrinology and Metabolism. 86 (7): 3284–3291. doi: 10.1210/jcem.86.7.7644 . PMID   11443202.
  43. ↑ "Methods of neuroendocrine regulation of affective disorders". United States Patent and Trademark Office . 20 January 1998. Archived from the original on 29 July 2018. Retrieved 12 October 2014.
  44. ↑ Lu, X.-Y.; Kim, C. S.; Frazer, A.; Zhang, W. (31 January 2006). "Leptin: a potential novel antidepressant". Proceedings of the National Academy of Sciences of the United States of America. 103 (5): 1593–1598. Bibcode:2006PNAS..103.1593L. doi: 10.1073/pnas.0508901103 . PMC   1360555 . PMID   16423896.
  45. ↑ Hirano, S.; Miyata, S.; Kamei, J. (January 2007). "Antidepressant-like effect of leptin in streptozotocin-induced diabetic mice". Pharmacology Biochemistry and Behavior. 86 (1): 27–31. doi:10.1016/j.pbb.2006.12.003. PMID   17258301. S2CID   41483918.
  46. ↑ Paz-Filho, G. J.; Babikian, T.; Asarnow, R.; Delibasi, T.; Esposito, K.; Erol, H. K.; Wong, M.-L.; Licinio, J. (29 August 2008). "Leptin replacement improves cognitive development". PLOS ONE. 3 (8): e3098. Bibcode:2008PLoSO...3.3098P. doi: 10.1371/journal.pone.0003098 . PMC   2518120 . PMID   18769731.
  47. ↑ "NIH Pharmacogenomics Research Network (PGRN)". NIH . 13 October 2014. Archived from the original on 19 October 2014. Retrieved 13 October 2014.
  48. ↑ International HapMap Consortium (June 2004). "Integrating ethics and science in the International HapMap Project". Nature Reviews Genetics. 5 (6): 467–475. doi:10.1038/nrg1351. PMC   2271136 . PMID   15153999.
  49. ↑ International HapMap 3 Consortium; Altshuler, D. M.; Gibbs, R. A.; Peltonen, L.; Altshuler, D. M.; Gibbs, R. A.; Peltonen, L.; Dermitzakis, E.; Schaffner, S. F.; Yu, F.; Peltonen, L.; Dermitzakis, E.; Bonnen, P. E.; Altshuler, D. M.; Gibbs, R. A.; de Bakker, P. I.; Deloukas, P.; Gabriel, S. B.; Gwilliam, R.; Hunt, S.; Inouye, M.; Jia, X.; Palotie, A.; Parkin, M.; Whittaker, P.; Yu, F.; Chang, K.; Hawes, A.; Lewis, L. R.; Ren, Y.; Wheeler, D.; Gibbs, R. A.; Muzny, D. M.; Barnes, C.; Darvishi, K.; Hurles, M.; Korn, J. M.; Kristiansson, K.; Lee, C.; McCarrol, S. A.; Nemesh, J.; Dermitzakis, E.; Keinan, A.; Montgomery, S. B.; Pollack, S.; Price, A. L.; Soranzo, N.; Bonnen, P. E.; Gibbs, R. A.; Gonzaga-Jauregui, C.; Keinan, A.; Price, A. L.; Yu, F.; Anttila, V.; Brodeur, W.; Daly, M. J.; Leslie, S.; McVean, G.; Moutsianas, L.; Nguyen, H.; Schaffner, S. F.; Zhang, Q.; Ghori, M. J.; McGinnis, R.; McLaren, W.; Pollack, S.; Price, A. L.; Schaffner, S. F.; Takeuchi, F.; Grossman, S. R.; Shlyakhter, I.; Hostetter, E. B.; Sabeti, P. C.; Adebamowo, C. A.; Foster, M. W.; Gordon, D. R.; Licinio, J; Manca, M. C; Marshall, P. A.; Matsuda, I.; Ngare, D.; Wang, V. O.; Reddy, D.; Rotimi, C. N.; Royal, C. D.; Sharp, R. R.; Zeng, C.; Brooks, L. D.; McEwen, J. E. (2 September 2010). "Integrating common and rare genetic variation in diverse human populations". Nature. 467 (7311): 52–58. Bibcode:2010Natur.467...52T. doi:10.1038/nature09298. PMC   3173859 . PMID   20811451.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  50. ↑ Licinio, J.; O'Kirwan, F.; Irizarry, K.; Merriman, B.; Thakur, S.; Jepson, R.; Lake, S.; Tantisira, K. G.; Weiss, S. T.; Wong, M.-L. (December 2004). "Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans". Molecular Psychiatry. 9 (12): 1075–1082. doi: 10.1038/sj.mp.4001587 . PMID   15365580.
  51. ↑ Ribeiro, L.; Busnello, J. V.; Cantor, R. M.; Whelan, F.; Whittaker, P.; Deloukas, P.; Wong, M.-L.; Licinio, J. (6 August 2007). "The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans". NeuroReport. 18 (12): 1291–1293. doi:10.1097/wnr.0b013e328273bcb0. PMC   2686836 . PMID   17632285.
  52. ↑ Wu, G. S.; Luo, H. R.; Dong, C.; Mastronardi, C.; Licinio, J.; Wong, M.-L. (May 2009). "Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response". Psychiatric Genetics. 21 (5): 14–18. doi:10.1097/YPG.0b013e32834133d2. hdl: 1885/65486 . PMC   9531708 . PMID   21052032. S2CID   32610262.
  53. ↑ Licinio, J.; Dong, C.; Wong, M.-L. (February 2011). "Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response". Archives of General Psychiatry. 66 (1): 488–497. doi:10.1001/archgenpsychiatry.2009.38. PMC   4272010 . PMID   19414708.
  54. ↑ Wong, M.-L.; Dong, C.; Flores, D. L.; Ehrhart-Bornstein, M.; Bornstein, S.; Arcos-Burgos, M.; Licinio, J. (15 September 2014). "Clinical Outcomes and Genome-Wide Association for a Brain Methylation Site in an Antidepressant Pharmacogenetics Study in Mexican Americans". American Journal of Psychiatry. 171 (12): 1297–309. doi:10.1176/appi.ajp.2014.12091165. PMC   5746054 . PMID   25220861.
  55. ↑ Licinio, J.; Wong, M.-L. (July 1999). "The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection". Molecular Psychiatry. 4 (4): 317–327. doi:10.1038/sj.mp.4000586. PMID   10483047. S2CID   493425.
  56. ↑ Licinio, J.; Wong, M.-L.; Gold, P. W. (July 1991). "Localization of interleukin-1 receptor antagonist mRNA in rat brain". Endocrinology. 129 (1): 562–564. doi:10.1210/endo-129-1-562. PMID   1829036.
  57. ↑ Licinio, J.; Wong, M.-L. (March 1994). "Localization of interleukin 1 type I receptor mRNA in rat brain". Neuroimmunomodulation. 1 (2): 110–115. doi:10.1159/000097143. PMID   7489320.
  58. ↑ Wong, M.-L.; Rettori, V.; al-Shekhlee, A.; Bongiorno, P. B.; Canteros, G.; McCann, S. M.; Gold, P. W.; Licinio, J. (May 1996). "Inducible nitric oxide synthase gene expression in the brain during systemic inflammation". Nature Medicine. 2 (5): 581–584. doi:10.1038/nm0596-581. PMID   8616720. S2CID   9942284.
  59. ↑ Loddick, S. A.; Wong, M.-L.; Bongiorno, P. B.; Gold, P. W.; Licinio, J.; Rothwell, N. J. (8 May 1997). "Endogenous interleukin-1 receptor antagonist is neuroprotective". Biochemical and Biophysical Research Communications. 234 (1): 211–215. doi:10.1006/bbrc.1997.6436. PMID   9168991.
  60. ↑ Wong, M.-L.; Bongiorno, P. B.; Rettori, V.; McCann, S. M.; Licinio, J.; Wong, M.-L. (7 January 1997). "Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications". Proceedings of the National Academy of Sciences of the United States of America. 94 (1): 227–232. Bibcode:1997PNAS...94..227W. doi: 10.1073/pnas.94.1.227 . PMC   19294 . PMID   8990190.
  61. ↑ Wong, M.-L.; Xie, B.; Beatini, N.; Phu, P.; Marathe, S.; Johns, A.; Gold, P. W.; Hirsch, E.; Williams, K. J.; Licinio, J.; Tabas, I. (18 July 2000). "Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis". Proceedings of the National Academy of Sciences of the United States of America. 97 (15): 8681–8686. Bibcode:2000PNAS...97.8681W. doi: 10.1073/pnas.150098097 . PMC   27008 . PMID   10890909.
  62. ↑ Mastronardi, C.; Whelan, F.; Yildiz, O. A.; Hannestad, J.; Elashoff, D.; McCann, S. M.; Licinio, J.; Wong, M.-L. (24 April 2007). "Caspase 1 deficiency reduces inflammation-induced brain transcription". Proceedings of the National Academy of Sciences of the United States of America. 104 (17): 7205–7210. Bibcode:2007PNAS..104.7205M. doi: 10.1073/pnas.0701366104 . PMC   1847598 . PMID   17409187.
  63. ↑ Graessler, J.; Qin, Y.; Zhong, H.; Zhang, J.; Licinio, J.; Wong, M.-L.; Xu, A.; Chavakis, T.; Bornstein, A. B.; Ehrhart-Bornstein, M.; Lamounier-Zepter, V.; Lohmann, T.; Wolf, T.; Bornstein, S. R. (December 2013). "Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters". The Pharmacogenomics Journal. 13 (6): 514–522. doi:10.1038/tpj.2012.43. PMID   23032991. S2CID   25565243.
  64. ↑ Zheng, P.; Zeng, B.; Zhou, C.; Liu, M.; Fang, Z.; Xu, X.; Zeng, L.; Chen, J.; Fan, S.; Du, X.; Zhang, X.; Yang, D.; Yang, Y.; Meng, H.; Li, W.; Melgiri, ND.; Licinio, J.; Wei, H.; Xie, P. (June 2016). "Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism". Molecular Psychiatry. 21 (6): 786–796. doi: 10.1038/mp.2016.44 . PMID   27067014. S2CID   9636895.
  65. ↑ Wong, M.-L.; Inserra, A.; Lewis, M. D.; Mastronardi, C. A.; Leong, L.; Choo, J.; Kentish, S.; Xie, P.; Morrison, M.; Wesselingh, S. L.; Rogers, G. B.; Licinio, J. (June 2016). "Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition". Molecular Psychiatry. 21 (6): 797–805. doi:10.1038/mp.2016.46. PMC   4879188 . PMID   27090302.
  66. ↑ Zheng, P.; Zeng, B.; Liu, M.; Chen, J.; Pan, J.; Han, Y.; Liu, Y.; Cheng, K.; Zhou, C.; Wang, H.; Zhou, X.; Gui, S.; Perry, S. W.; Wong, M.-L.; Licinio, J.; Wei, H.; Xie, P. (6 February 2019). "The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice". Science Advances. 5 (2): eaau8317. Bibcode:2019SciA....5.8317Z. doi:10.1126/sciadv.aau8317. PMC   6365110 . PMID   30775438.
  67. ↑ Rogers, G. B.; Keating, D. J.; Young, R. L.; Wong, M.-L.; Licinio, J.; Wesselingh S. (June 2016). "From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways". Molecular Psychiatry. 21 (6): 738–748. doi:10.1038/mp.2016.50. PMC   4879184 . PMID   27090305.
  68. ↑ Inserra, A.; Rogers, G. B.; Licinio, J.; Wong, M.-L. (September 2018). "The microbiota-inflammasome hypothesis of major depression". BioEssays. 40 (9): e1800027. doi: 10.1002/bies.201800027 . PMID   30004130.
  69. ↑ Inserra, A.; Choo, J. M.; Lewis, M. D.; Rogers, G. B.; Wong, M.-L.; Licinio, J. (23 April 2019). "Mice lacking Casp1, Ifngr and Nos2 genes exhibit altered depressive- and anxiety-like behaviour, and gut microbiome composition". Scientific Reports. 9 (1): 6456. Bibcode:2019NatSR...9.6456I. doi:10.1038/s41598-018-38055-8. PMC   6478737 . PMID   31015500.
  70. ↑ Licinio, J.; Womg, M.-L. (23 September 2021). "Climate change and mental health: a commentary". Discover Mental Health. 1 (1): 1. doi: 10.1007/s44192-021-00001-y . PMC   10498147 . PMID   37861755.
  71. ↑ "Springer Nature SDG Programme SDG 13: Climate Action". 19 October 2021.
  72. ↑ Licinio, Julio (21 June 2013). "Diagnosing Madness". Science . 340 (6139): 1406–1407. Bibcode:2013Sci...340.1406L. doi:10.1126/science.1236286. S2CID   220077940.
  73. ↑ Licinio, Julio (23 February 2001). "An Internet Tea Party". Science . 291 (5508): 1493–1495. doi:10.1126/science.291.5508.1493. S2CID   161681908.
  74. ↑ Licinio, Julio (1 October 1999). "What Makes One Tic?". Science . 286 (5437): 56–57. doi:10.1126/science.286.5437.56. S2CID   142559400.
  75. ↑ Licinio, Julio (18 December 1998). "Expressing Freudian Influences". Science . 282 (5397): 2197–2198. doi:10.1126/science.282.5397.2197. S2CID   194011406.
  76. ↑ "Julio Licinio's Blog: Discovery to change your life". 15 October 2014. Archived from the original on 22 October 2014. Retrieved 15 October 2014.
  77. ↑ "The New York State Suicide Prevention Task Force Report" (PDF). April 2019. Retrieved 24 July 2020.
  78. ↑ "PubMed authors Licinio J and Wong ML". PubMed . 12 October 2014. Archived from the original on 16 October 2014. Retrieved 12 October 2014.
  79. ↑ Licinio, J.; Wong, M.-L. (February 2005). "Opinion: Depression, antidepressants and suicidality: a critical appraisal". Nature Reviews Drug Discovery. 4 (2): 165–171. doi:10.1038/nrd1634. PMID   15688079. S2CID   35880869.
  80. ↑ Licinio, Julio; Wong, Ma-Li, eds. (12 October 2014). Pharmacogenomics: The Search for Individualized Therapies. Wiley Online Library. doi:10.1002/3527600752. ISBN   978-3527303809. S2CID   215530144.
  81. ↑ Licinio, Julio; Wong, Ma-Li, eds. (12 October 2014). Biology of Depression: From Novel Insights to Therapeutic Strategies. Wiley Online Library. doi:10.1002/9783527619672. ISBN   9783527619672.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.